Innovating Works

ICM-VAL D'AURELLE

A stranger
MR O MICS: Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging INSTITUT REGIONAL DU CANCER DE MONTPELLIER processed a HORIZON EUROPE ERC-2022-STG High-grade serous ovarian cancer (HGSOC) is the most common subtype of ovarian cancer. The early rapid onset of chemoresistance poses a majo...
2023-08-13 - 2028-08-31 | financed
LIMA: Liquid biopsies and Imaging for improved cancer care INSTITUT REGIONAL DU CANCER DE MONTPELLIER participó en un H2020 H2020-SC1-2016-2017 LIMA’s overall objective is to develop and validate technologies and tools to include liquid biopsies in the clinical workflow, aiming at in...
2017-11-21 - 2022-06-30 | financed
REQUITE: Validating predictive models of radiotherapy toxicity to improve quality of life and reduce side eff... INSTITUT REGIONAL DU CANCER DE MONTPELLIER participó en un FP7 Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predi...
financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.